Memorial Hermann has been recognized for its overall performance in serving both individuals and the community. Photo via memorialhermann.org

Houston hospitals have been evaluated by a new ranking to determine the institutions that are doing their best to serve their patients and the community as a whole.

Brookline, Massachusetts-based think tank, The Lown Institute, has revealed its national rankings on its Lown Institute Hospitals Index — which evaluated hospitals based on civic leadership (based on inclusion and access), value of care, and patient outcomes (which evaluates safety and satisfaction).

"At a time when communities are relying on them like never before, hospitals must rethink what it means to be great," says Dr. Vikas Saini, president of the Lown Institute, in a news release. "COVID-19 highlights how hospitals are essential community partners for anyone in need. To be great, however, a hospital cannot only provide care that's high in quality. It must also deliver value and advance equality. Our index is designed to help them do just that."

The Texas Medical Center's Memorial Hermann Hospital ranked as No. 9 on the list that evaluated over 3,000 hospitals in the country. The hospitals are also given a grade on each of the three categories. Memorial Hermann received an A for civic leadership, an A- for value of care, and an A+ for patient outcomes — for an overall A+ grade.

Based on ranking, the Houston area's top 10 hospitals, which all received an overall grade of A- or above, are:

  1. Memorial Hermann Texas Medical Center (No. 9 in the country; No. 3 in the state)
  2. Harris Health System (No. 23 in the country; No. 5 in the state)
  3. Memorial Hermann Northeast Hospital in Humble (No. 165 in the country; No. 15 in the state)
  4. Memorial Hermann Hospital System (No. 297 in the country; No. 17 in the state)
  5. Brazosport Regional Health System in Lake Jackson (No. 304 in the country; No. 18 in the state)
  6. The Woman's Hospital of Texas (No. 373 in the country; No. 25 in the state)
  7. Memorial Hermann Katy Hospital in Katy (No. 374 in the country; No. 26 in the state)
  8. Houston Methodist San Jacinto Hospital in Baytown (No. 627 in the country; No. 43 in the state)
  9. Memorial Hermann Sugar Land Hospital in Sugar Land (No. 648 in the country; No. 44 in the state)
  10. Memorial Hermann Memorial City Medical Center (No. 652 in the country; No. 45 in the state)

The Harris Health System ranked the highest in Houston for civic leadership, and the Memorial Hermann Memorial City Medical Center scored the highest in the region for patient outcomes.

There were three other Texas hospitals among the top 10 in the nation — JPS Health Network in Fort Worth ranked as No. 1, Seton Northwest Hospital in Austin ranked as No. 4, and Parkland Health and Hospital System in Dallas ranked as No. 10.

The point of the study, according to the release, is to hold hospitals accountable for more than just one factor of success.

"There are some very fine hospitals that feel forced to focus on profitable elective procedures to stay in business," says Saini in the release. "This can lead to business decisions that make them look good on outcomes like mortality, but at the expense of equity. The data show that gaps between a hospital's clinical results and its performance in the community are sometimes very wide, which can contribute to disparities in care and put certain communities at risk."

The study factored in data from a variety of sources, including the 100 percent Medicare claims datasets (MEDPAR and outpatient); Internal Revenue Service pulled from Community Benefit Insight database; Healthcare Cost Report Information System administered by the Centers for Medicare and Medicaid Services; Securities and Exchange Commission filings; public records; Bureau of Labor Statistics; and other databases, according to the release.

"No other hospital ranking provides a 360-degree view of hospital performance," says Shannon Brownlee, senior vice president at the Lown Institute, in the release. "Many of the best-known hospitals score highly on patient outcomes but poorly on civic leadership and value of care. Our data show that it's possible to do well in all three categories, because some hospitals are doing it. That means all the people in their communities are being served effectively and fairly."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.